Early Assessment of Teplizumab Treatment Response Using Continuous Glucose Monitoring
Authors' conclusion
These observations suggest that CGM may capture early directional changes in glycemic dynamics following immunomodulatory therapy and may provide a practical approach for longitudinal monitoring.
Study context
- Population
- Children with stage 2 T1D treated with teplizumab
- Participants
- 5 children
- Outcome
- Continuous glucose monitoring (CGM) trajectories (GV, time above 140 mg/dL)
- Follow-up
- 8-19 months
Methodological detailsreal-world setting, longitudinal
- Real-world setting
- Longitudinal
Main finding
As reported in the abstract
Remained in stage 2
4 participants
Progressed to stage 3 diabetes within 4 months of treatment
1 participant
Observational data: associations, not effects.
Original publication
Early Assessment of Teplizumab Treatment Response Using Continuous Glucose Monitoring. Diabetes Technol Ther. Published 10 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →